Literature DB >> 10701840

The Hsp90-specific inhibitor geldanamycin selectively disrupts kinase-mediated signaling events of T-lymphocyte activation.

T Schnaider1, J Somogyi, P Csermely, M Szamel.   

Abstract

The 90-kDa heat shock protein (Hsp90) is the most abundant molecular chaperone of eukaryotic cells. Its chaperone function in folding nascent proteins seems to be restricted to a subset of proteins including major components of signal transduction pathways (eg, nuclear hormone receptors, transcription factors, and protein kinases). Improper function of these proteins can be induced by selective disruption of their complexes with Hsp90 using the benzoquinonoid ansamycin geldanamycin. In this study, we demonstrate that geldanamycin treatment blocks interleukin (IL)-2 secretion, IL-2 receptor expression, and proliferation of stimulated T-lymphocytes. Moreover, geldanamycin decreases the amount and phosphorylation of Lck and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase. Geldanamycin also disrupts the T-cell receptor-mediated activation of nuclear factor of activated T-cells (NF-AT). Treatment with geldanamycin, however, does not affect the activation of lysophosphatide acyltransferase, which is a plasma membrane enzyme coupled to the T-cell receptor after T-cell stimulation. Through demonstrating the selective inhibition of kinase-related T-lymphocyte responses by geldanamycin, our results emphasize the substantial role of Hsp90-kinase complexes in T-cell activation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10701840      PMCID: PMC312910     

Source DB:  PubMed          Journal:  Cell Stress Chaperones        ISSN: 1355-8145            Impact factor:   3.667


  42 in total

1.  Proteins, RNAs and chaperones in enzyme evolution: a folding perspective.

Authors:  P Csermely
Journal:  Trends Biochem Sci       Date:  1997-05       Impact factor: 13.807

2.  The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinase.

Authors:  L F Stancato; A M Silverstein; J K Owens-Grillo; Y H Chow; R Jove; W B Pratt
Journal:  J Biol Chem       Date:  1997-02-14       Impact factor: 5.157

Review 3.  The role of the hsp90-based chaperone system in signal transduction by nuclear receptors and receptors signaling via MAP kinase.

Authors:  W B Pratt
Journal:  Annu Rev Pharmacol Toxicol       Date:  1997       Impact factor: 13.820

4.  Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent.

Authors:  C E Stebbins; A A Russo; C Schneider; N Rosen; F U Hartl; N P Pavletich
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

5.  Hsp90-mediated folding of the lymphoid cell kinase p56lck.

Authors:  S D Hartson; D J Barrett; P Burn; R L Matts
Journal:  Biochemistry       Date:  1996-10-15       Impact factor: 3.162

Review 6.  T cell antigen receptor signal transduction pathways.

Authors:  D Cantrell
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

Review 7.  T cell antigen receptor signal transduction.

Authors:  D Qian; A Weiss
Journal:  Curr Opin Cell Biol       Date:  1997-04       Impact factor: 8.382

8.  T cell antigen receptor dependent signalling in human lymphocytes: cholera toxin inhibits interleukin-2 receptor expression but not interleukin-2 synthesis by preventing activation of a protein kinase C isotype, PKC-alpha.

Authors:  M Szamel; U Ebel; P Uciechowski; V Kaever; K Resch
Journal:  Biochim Biophys Acta       Date:  1997-04-24

9.  Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced Her-2/neu activation, receptor expression and proliferation of Her-2-positive malignant cell lines.

Authors:  F Hartmann; E M Horak; C Cho; R Lupu; J B Bolen; M A Stetler-Stevenson; M Pfreundschuh; T A Waldmann; I D Horak
Journal:  Int J Cancer       Date:  1997-01-17       Impact factor: 7.396

10.  Age-related decline of rat liver multicatalytic proteinase activity and protection from oxidative inactivation by heat-shock protein 90.

Authors:  M Conconi; L I Szweda; R L Levine; E R Stadtman; B Friguet
Journal:  Arch Biochem Biophys       Date:  1996-07-15       Impact factor: 4.013

View more
  13 in total

Review 1.  Aging and immune function: molecular mechanisms to interventions.

Authors:  Subramaniam Ponnappan; Usha Ponnappan
Journal:  Antioxid Redox Signal       Date:  2011-01-08       Impact factor: 8.401

2.  The 90-kDa heat shock protein Hsp90 protects tubulin against thermal denaturation.

Authors:  Felix Weis; Laura Moullintraffort; Claire Heichette; Denis Chrétien; Cyrille Garnier
Journal:  J Biol Chem       Date:  2010-01-28       Impact factor: 5.157

3.  Dynamic tyrosine phosphorylation modulates cycling of the HSP90-P50(CDC37)-AHA1 chaperone machine.

Authors:  Wanping Xu; Mehdi Mollapour; Chrisostomos Prodromou; Suiquan Wang; Bradley T Scroggins; Zach Palchick; Kristin Beebe; Marco Siderius; Min-Jung Lee; Anthony Couvillon; Jane B Trepel; Yoshihiko Miyata; Robert Matts; Len Neckers
Journal:  Mol Cell       Date:  2012-06-21       Impact factor: 17.970

4.  Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells.

Authors:  Jooeun Bae; Aditya Munshi; Cheng Li; Mehmet Samur; Rao Prabhala; Constantine Mitsiades; Kenneth C Anderson; Nikhil C Munshi
Journal:  J Immunol       Date:  2013-01-04       Impact factor: 5.422

5.  Role of the heat shock protein 90 in immune response stimulation by bacterial DNA and synthetic oligonucleotides.

Authors:  F G Zhu; D S Pisetsky
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

6.  Heat shock protein 90 is a new potential target of anti-rejection therapy in allotransplantation.

Authors:  Takeshi Maehana; Toshiaki Tanaka; Kohei Hashimoto; Ko Kobayashi; Hiroshi Kitamura; Naoya Masumori
Journal:  Cell Stress Chaperones       Date:  2022-04-09       Impact factor: 3.827

Review 7.  Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy.

Authors:  S V Alarcon; M Mollapour; M-J Lee; S Tsutsumi; S Lee; Y S Kim; T Prince; A B Apolo; G Giaccone; W Xu; L M Neckers; J B Trepel
Journal:  Curr Mol Med       Date:  2012-11-01       Impact factor: 2.222

8.  The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus.

Authors:  Yuan Liu; Josephine Ye; Luisa Shin Ogawa; Takayo Inoue; Qin Huang; John Chu; Richard C Bates; Weiwen Ying; Andrew J Sonderfan; Patricia E Rao; Dan Zhou
Journal:  PLoS One       Date:  2015-05-14       Impact factor: 3.240

9.  Defect in HSP90 expression in highly differentiated human CD8(+) T lymphocytes.

Authors:  O Franzese; S M Henson; C Naro; E Bonmassar
Journal:  Cell Death Dis       Date:  2014-06-12       Impact factor: 8.469

10.  Geldanamycin-mediated inhibition of heat shock protein 90 partially activates dendritic cells, but interferes with their full maturation, accompanied by impaired upregulation of RelB.

Authors:  Stefanie Trojandt; Angelika B Reske-Kunz; Matthias Bros
Journal:  J Exp Clin Cancer Res       Date:  2014-02-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.